Genome Editing Market – Industry Report & Statistics (Demand & Sales by Technology & Application)

Market Size & Growth Outlook

The global genome editing market was valued at USD 5.06 billion in 2021 and is projected to reach USD 21.36 billion by 2030, expanding at a CAGR of 17.33% (Strategic Market Research).

Genome editing (also referred to as gene editing or genome engineering) involves the modification of genetic material within an organism’s DNA to study functional changes and develop therapeutic or agricultural improvements. Applications include the treatment of single nucleotide polymorphisms (SNPs), cystic fibrosis (CF), hemophilia, and sickle cell disease, as well as endogenous gene labeling, embryo genome editing, targeted transgene addition, and prevention of endemic diseases such as malaria and diarrhea.

---

Market Dynamics

Key Growth Drivers

1. Advances in CRISPR Technology

   • The discovery of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), which won the 2020 Nobel Prize in Chemistry, has accelerated adoption.
   • A 2020 clinical trial using CRISPR for chromosome rearrangement in multiple myeloma patients demonstrated tumor growth suppression in one case, highlighting its potential in oncology.
   • Strategic Market Research (SMR) reported that CRISPR with Pro-code technology is ~75% more efficient in breast cancer screening compared to alternative methods.

2. Agricultural Applications

   • Gene editing was applied to white button mushrooms by modifying polyphenol oxidase (PPO) genes, reducing browning by 30%.
   • The FDA cleared these mushrooms for cultivation without regulatory oversight, underscoring the potential of genome editing in agriculture.
   • Expanding research in plant, animal, and healthcare applications is expected to sustain long-term market growth.

3. Rising Prevalence of Genetic Disorders

   • Genetic disorders arise from mutations or abnormal gene dosage.
   • According to the U.S. Genetic and Rare Disease Information Center, nearly 30 million Americans (1 in 10) are affected by genetic or rare diseases.
   • The WHO reports that 2–5% of live births present with congenital abnormalities, accounting for ~30% of pediatric hospital admissions.
   • Congenital malformations are the leading cause of infant mortality in the UAE and a major cause in Qatar, Oman, Bahrain, and Kuwait.
   • This rising prevalence underscores the urgent need for genome editing solutions and therapeutic development.

4. Investment Momentum

   • Since the discovery of CRISPR, investment in genome editing has surged.
   • In 2021, the sector raised USD 1.3 billion across 18 CRISPR-related deals.
   • Mammoth Biosciences secured the largest funding round, aimed at advancing next-generation CRISPR technologies.
   • Increased capital inflows are expected to accelerate innovation and commercialization.

---

Opportunities

1. Cancer Research Applications

   • Cancer caused ~10 million deaths globally in 2020 (WHO).
   • Leading causes include:
     • Lung cancer: 1.81 million deaths
     • Colorectal cancer: ~916,000 deaths
     • Liver cancer: ~830,000 deaths
     • Stomach cancer: ~769,000 deaths
     • Breast cancer: ~685,000 deaths (90% in women)
   • Studies show CRISPR/Cas9 can inhibit cancer cell proliferation.
   • Research into somatic cell therapies presents significant opportunities for cancer treatment and prevention.

2. Plant Genetic Engineering

   • Genome editing is widely applied in agriculture for commercial crop development.
   • According to the International Service for the Acquisition of Agro-biotech Applications (ISAAA):
     • In India, Bt cotton accounts for 80% of 12 million hectares of cotton cultivation.
   • The FDA reports that ~95% of U.S. corn, soybean, cotton, sugar beet, and canola crops are grown using genetically modified (GM) seeds.
   • Continued research in plant genome engineering is expected to expand applications for botanists and agriculturists, driving market growth.

---

Restraints

• Regulatory Delays: Long approval timelines for genetically modified (GM) products hinder commercialization.
• Public Perception & Misinformation: Widespread skepticism and misinformation regarding genetically engineered products remain significant barriers to adoption.

---

Strategic Outlook

The genome editing market is positioned for sustained high growth, driven by:

• CRISPR-led innovation in healthcare and agriculture
• Rising prevalence of genetic disorders
• Expanding investment pipelines
• Opportunities in oncology and plant biotechnology

However, regulatory hurdles and public perception challenges must be addressed to fully realize the sector’s potential.

 

.

 

Report Attribute	Details
Period of Forecast	2021 - 2030
The Market size value in 2021	USD 5.06 billion
The Revenue forecast in 2030	USD 21.39 billion
Growth rate	CAGR of 17.33 %
The base year for estimation	2021
Historical data	2017 – 2020
Unit	USD Billion, CAGR (2021 - 2030)
Segmentation	Product and service, application, technology, end-users, and region.
By Product and Service	Consumables, Reagents, Services, Software, and Systems.
By Application	Cell Line Engineering, Diagnostic applications, Drug discovery and development, Plant Genetic Engineering, Animal Genetic Engineering, and Other applications.
By Technology	Antisense, CRISPR, TALEN, ZFN, and Other technologies.
By Region	North America, Europe, Asia-Pacific, and LAMEA
By end-users	Academic Research Institutes, Biotechnology companies, Government Research Institutes and Pharmaceutical companies.
Country Scope	USA, Canada, India, Vietnam, China, Russia, Australia, The Netherlands, France, Germany, Singapore, and Switzerland.
Company Usability Profiles	Agilent Technologies, Beam Therapeutics, Beren Therapeutics, Bluebird Bio, Caribou Biosciences, Inc., Cellectis S.A, Creative Biogene, CRISPR Therapeutics AG, Editas Medicine, Eurofins Scientific, GenScript, Horizon Discovery Group plc., Integrated DNA Technologies, Inc., Intellia Therapeutics, Inc., Lonza, Merck KGaA, New England Biolabs, OriGene Technologies, PerkinElmer, Precision Biosciences, Recombinetics, Regeneron Pharmaceuticals, Sangamo Therapeutics, Inc., Synthego, Tecan Life Sciences, Thermo Fisher Scientific Inc., Transposagen Biopharmaceuticals, and Vigene Biosciences.

 

 

 

Global Genome Editing Market Competitive Landscape Analysis

• Beam Therapeutics

• Agilent Technologies

• Bluebird Bio

• Caribou Biosciences

• Beren Therapeutics

• Cellectis S.A

• Editas Medicine

• Creative Biogene

• Eurofins Scientific

• CRISPR Therapeutics

• Intellia Therapeutics

• Horizon Discovery Group plc.

• Integrated DNA Technologie

• Lonza

• GenScript

• Merck

• OriGene Technologies

• New England Biolabs

• Precision Biosciences

• PerkinElmer

• Regeneron Pharmaceuticals

• Recombinetics

• Synthego

• Sangamo Therapeutics

• Thermo Fisher-Scientific

• Vigene Biosciences

• Tecan Life-Sciences 

• Trans-posagen Bio-pharmaceuticals

 

 

Recent Developments:

• In July 2022, a research team at the University of California, San Diego, found a new technique to 'repair' genetic defects. By using “soft” CRISPR, the scientists were able to target only a single strand of DNA to develop red-eye color in fruit flies. Their objective is to further carry out experiments to make it viable to treat and cure human genetic diseases.

 

• In July 2022, Verve Therapeutics' clinical trial on a patient involved the injection of a gene-editing drug to lower LDL cholesterol. The patient suffered from cardiac disease and had an extremely high cholesterol level. The aim is to conduct further trials to prevent high LDL levels, thereby preventing cardiovascular diseases. If the drug works, it would be offered as a one-time shot to lower the high LDL levels in patients and address the primary cause of death in the US -heart disease.

 

• In July 2022, a study found that Nothobranchius furzeri (N. furzeri), commonly called the African turquoise killifish, can be used as an organism to study vertebral aging. The fish was modified using the gene knockout method to further make them viable for studies on aging and embryonic diapause. These methods reduce the experiment duration and facilitates rapid identification of the genes.

 

• In July 2022, the president of Italy's Commission for Agriculture presented a law that would enable genome editing companies to provide seeds to ensure higher yield and lower water consumption to fight with the drastic climate changes. The matter would be deliberated in the parliament and is expected to become an act primarily benefitting farmers and agro-biotech companies.

 

• In May 2022, the English parliament introduced a Bill that would enable the release of genetically edited products. The Genetic Technology (Precision Breeding) Bill aims to benefit companies, farmers, and consumers. The bill is currently under the report stage in the House of Commons.

 

• In July 2022, researchers at the Indiana Center for Regenerative Medicine and Engineering developed a technology that is able to regenerate tissue in a live body. Tissue Nano transfection (TNT) was developed using gene editing technology and aimed to assist in the treatment of crushed nerves, diabetic retinopathy, injured legs, and brains affected by stroke.